REFERENCES
- Staszewski S, Morales-Ramirez J, Tashima K, et al. Efa-virenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New Engl J Med. 1999;341:1865–1873.
- Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treat-ment of adult HIV infection: 2008 recommendations of the International AIDS Society - USA Panel. JAMA. 2008;300(5):555–570.
- Bristol-Myers Squibb. Sustiva® (efavirenz) package insert. PDR net®. 2008.
- Clifford DB, Evans S, Yang Y, et al. Impact on efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143: 714–721.
- Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nu-cleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850–1861.
- Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection. A randomized control trial. JAMA. 2006;296:769–781.
- Wechsler D. Wechsler Adult Intelligence Scale (WAIS-III) - Administration and scoring manual. 3rd ed. San Antonio, TX: Psychological Corp.; 1997.
- Buysse DJ, Reynold CF, Monk TH, Kupfer DF. The Pitts-burgh Sleep Quality Index: a new instrument for psy-chiatric practice and research. Psychiatry Research. 1989;28:193–213.
- Spielberger CD. State-Trait Anxiety Inventory for Adults (Form Y). Redwood City, CA: Mind Garden; 1983.
- Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measure. 1977;1:385–401.
- Turner ML, Reed-Walker K, King JR, Acosta EP. Simultane-ous quantitation of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma using a single high-performance liquid chromatography methodol-ogy. J Chromatog B. 2003;784:331–341.
- Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 1999;13: 1249–1253.
- Sacktor N, McDermott MP, Marder K, et al. HIV-associ-ated cognitive impairment before and after the advent of combination therapy. J NeuroVirol. 2002;8:136–142.
- Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65–70.
- Tashima K, Caliendo AM, Ahmad M, et al. Cerebrospi-nal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis. 1999;180:862–864.
- Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinua-tion: an adult AIDS Clinical Trials Group study. Clin Infect Dis. 2005;42:401–407.
- Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 200115: 71–75.
- Rihs TA, Begley K, Smith DE, et al. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med. 2006;7:544–548.